The decades long quest for a treatment to protect all infants from respiratory syncytial virus (RSV) infection is coming to fruition as Sanofi and AstraZeneca PLC’s monoclonal antibody nirsevimab is now under review at the US Food and Drug Administration. If approved, the product would be the first treatment to prevent RSV in all newborns and infants.
Swedish Orphan Biovitrum AB (Sobi)’s Synagis (palivizumab) has been the sole treatment option. However, it is indicated only for children at high risk of RSV disease, including those born prematurely and those with bronchopulmonary dysplasia or certain types of congenital heart disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?